Edgar Filing: Insys Therapeutics, Inc. - Form 4

Insys Therapeut	tics, Inc.										
Form 4											
March 12, 2015										PROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB OMB Number:	3235-0287		
Section 16. Form 4 or Form 5 Filed pursuant to Sect				HANGES IN BENEFICIAL OWNERSHIP SECURITIES tion 16(a) of the Securities Exchange Act of 19					Expires:January 31Expires:200Estimated averageburden hours perresponse0.		
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section See Instruction 30(h) of the Investment Company Act of 1940 1(b).											
(Print or Type Resp	oonses)										
FOURTEAU PATRICK Symbolic Symb			Symbol	ol				5. Relationship of Reporting Person(s) to Issuer			
			Insys Therapeutics, Inc. [INSY]					(Check all applicable)			
(Mon			(Month/	3/11/2015				_X_Director10% Owner Officer (give titleOther (specify below) below)			
			4. If Am	Amendment, Date Original			6. Individual or Joint/Group Filing(Check				
							Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
		(7:)						Person			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Secu	rities Acqu	ired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution D any (Month/Day(Instr. 3)		Date, if Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) ay/Year) (Instr. 8)			5. Amount of Securities Beneficially Owned Following Reported	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code V	Amount	(A) or (D)	Price \$	Transaction(s) (Instr. 3 and 4)	(Instr. 4)		
Common 03/ Stock	/11/2015			S	10,000	D	59.9359 (<u>1)</u>	9 70,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date (Month/Day/Year)		7. Titl Amou Under Secur (Instr.	ınt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: Insys Therapeutics, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships							
Treporting of the Trans, Transies	Director	10% Owner	Officer	Other				
FOURTEAU PATRICK C/O INSYS THERAPEUTICS, INC. 444 SOUTH ELLIS STREET CHANDLER, AZ 85224	Х							
Signatures								
/s/ Darryl S. Baker, Attorney-in-Fact	03/11	03/11/2015						
<u>**</u> Signature of Reporting Person	Da	ite						
Explanation of Responses:								

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The weighted average sales price for the transaction reported was \$59.9359, and the range of prices were between \$59.50 to \$60.15.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.